The UC Davis MIND Institute IDDRC proposes a Research Project relevant to the Multi-modal Treatment Approaches theme that spans basic and clinical science and utilizes five of the proposed cores. Recent advances in the neurobiology of fragile X syndrome (FXS) have led to targeted treatments that rescue many phenotypic features in the FMRI knock out (KO) mouse and other animal models (Berry-Kravis et al., 2011;Bhakar et al., 2012;Hagerman et al., 2012). Many of these treatments are based on the mGluRS (metabotropic glutamate receptor 5) theory of FXS, which proposes that absence or reduction of FMRP in the full mutation leads to hypersensitivity of the mGluRS pathway to glutamate, which causes intellectual impairments, seizures, and other features of FXS (Bear et al., 2004;Dolen et al., 2007;Huber et al., 2002; Osterweil et al., 2010). In fact, mGluRS antagonists have proven effective in rescuing several FXS-related phenotypes in rodents (Dolen et al., 2010). In contrast to animal studies, therapeutic approaches targeting mGluRS show only modest efficacy in humans (Berry-Kravis et al., 2012). Three factors have contributed to the human findings, (a) Multiple pathways are affected in FXS;thus, targeting only a single pathway is unlikely to fully correct the complex phenotype. Additional targets must be identified so that a polypharmaceutical approach can be developed, (b) The outcome measures used in many clinical trials are not adequate for detecting subtle but meaningful treatment effects. (3) Important treatment-induced changes in brain function may produce only modest short-term changes in observable behavior in individuals with FXS, who have a history of missed and non-normative learning opportunities prior to treatment. It may be possible, however, to "boost" the phenotypic effects of a drug by adding a behavioral intervention to take advantage of improved brain function.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54HD079125-01
Application #
8659092
Study Section
Special Emphasis Panel (ZHD1-DSR-H (50))
Project Start
2013-09-24
Project End
2018-06-30
Budget Start
2013-09-24
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$421,754
Indirect Cost
$147,888
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Flannery, Brenna M; Silverman, Jill L; Bruun, Donald A et al. (2015) Behavioral assessment of NIH Swiss mice acutely intoxicated with tetramethylenedisulfotetramine. Neurotoxicol Teratol 47:36-45
Klusek, Jessica; Roberts, Jane E; Losh, Molly (2015) Cardiac autonomic regulation in autism and Fragile X syndrome: a review. Psychol Bull 141:141-75
Walker, Cheryl K; Krakowiak, Paula; Baker, Alice et al. (2015) Preeclampsia, placental insufficiency, and autism spectrum disorder or developmental delay. JAMA Pediatr 169:154-62
Channell, Marie Moore; Thurman, Angela John; Kover, Sara Teresa et al. (2014) Patterns of change in nonverbal cognition in adolescents with Down syndrome. Res Dev Disabil 35:2933-41
Benjamin, David P; Mastergeorge, Ann M; McDuffie, Andrea S et al. (2014) Effects of labeling and pointing on object gaze in boys with fragile X syndrome: an eye-tracking study. Res Dev Disabil 35:2658-72